NEK2 (NIMA-related expressed kinase 2) is a serine/threonine centrosomal kinase that acts as a critical regulator of centrosome structure and function. Aberrant NEK2 activities lead to failure in regulating centrosome duplication. NEK2 overexpression promotes tumorigenesis and is associated with poor prognosis in several cancers. Increased NEK2 expression during the late pathological stage has been detected in the Oncomine liver dataset and hepatocellular carcinoma (HCC) specimens. Elevated NEK2 protein is associated with poor overall survival in patients with HCC. However, the precise roles and mechanisms of NEK2 in liver cancer progression remain largely unknown. An earlier functional study revealed that NEK2 mediates drug resistance (cisplatin or lipo-doxorubicin) via expression of an ABCC10 transporter. Active angiogenesis and metastasis underlie the rapid recurrence and poor survival of HCC. Results from the current study showed that NEK2 mediates tumor growth, metastasis and angiogenesis in vivo. NEK2-mediated drug resistance was blocked by a specific PI3K or AKT inhibitor. Moreover, NEK2 mediated liver cancer cell migration via pAKT/NF-jB signaling and matrix metalloproteinase (MMP) activation. Angiogenesis was induced via the same signaling pathway and IL-8 stimulation. Our findings collectively indicate that NEK2 modulates hepatoma cell functions, including growth, drug resistance, metastasis and angiogenesis via downstream genes activation.
NEK2 [NIMA (never in mitosis gene A)-related expressed kinase 2)], a serine/threonine centrosomal kinase, is highly expressed and activated during the S and G2 phases of the cell cycle.
1 NEK2 has emerged as an important oncogene with a regulatory role in mitosis. 2 Previous studies have reported elevation of NEK2 expression in various cancer cell lines, including primary and invasive breast tumors. 3 Overexpression of NEK2 leads to premature centrosome splitting, concomitant with centrosomal abnormalities, monopolar spindles and aneuploidy. 4, 5 Increased expression of NEK2
and cyclin D1/Cdk4 has been shown to trigger centrosome amplification in breast cancer cells via oncogenic K-RAS activation. 6 Moreover, phosphorylation of the mitotic regulator, HEC1, mediated by NEK2 is required for faithful chromosome segregation. 7 A novel role of NEK2 has been reported whereby alternative splicing regulation of anti-apoptosis genes induced by NEK2 leads to oncogenic function. 8 High expression of NEK2 induces drug resistance in myeloma and breast cancers. 2, 3 Several studies have demonstrated pivotal roles of NEK2 in the development of various cancer types. For instance, NEK2 was shown to be overexpressed in cancer spheres, compared with parental cells in vitro, 9 leading to the suggestion that NEK2 activation contributes to tumorigenesis and progression of HCC and colon cancer. NEK2 is associated with poor prognosis in myeloma, and considered a crucial target for cancer therapy. 10 Recent reports additionally showed that overexpression of NEK2 is correlated with poor prognosis of primary liver cancer. 11 Knockdown of NEK2 in HepG2 cells may repress its function via inhibition of MAPK pathway activation. However, the association of NEK2 with drug resistance and other critical functions in liver cancer progression remains to be addressed. Previous reports have shown that NEK2 siRNA reduces the tumor volume in mouse xenografts. 12, 13 NEK2 depletion in cholangiocarcinoma cell lines triggered growth suppression and cell death, and administration of short interfering RNA (siRNA) against NEK2 into tumor-bearing mice induced substantial prolongation of survival. 14 NEK2 plays a critical role in mitosis during the cell division process. 15 Uncontrolled
Nek2 activity can lead to chromosome instability as well as abnormal chromosome content of a normal diploid cell. 16 These findings collectively suggest that NEK2 regulates tumor progression in vivo, supporting its targeted inhibition as an attractive strategy for anti-cancer therapeutic development. Hepatocellular carcinoma (HCC) is a highly vascularized tumor with frequent intrahepatic metastasis. 17 Active angiogenesis and metastasis are responsible for rapid recurrence and poor survival of HCC. 17 While NEK2 is clearly overexpressed in several cancers, NEK2-mediated functions, including metastasis and angiogenesis, involved in liver cancer progression remain to be clarified. In the current study, we further established that NEK2 overexpression contributes to drug resistance, metastasis and angiogenesis in liver cancer on the basis of clinical dataset and clinical specimen analyses.
Materials and Methods

Human HCC specimens and cancer cell lines
Clinical data for 160 HCC patients with total removal of liver tumors from January 2005 to December 2010 in the Chang Gung Medical Center, Taiwan, were reviewed with the approval of the institutional review board (IRB, No: 100-0622B). All samples were frozen at 2708C immediately after surgical resection. 
Quantitative reverse transcription-polymerase chain reaction (qRT-PCR)
Real-time qRT-PCR was conducted in a 15 ll reaction mixture containing 25 nM forward and reverse primers, 13 SYBR Green reaction mix (Applied Biosystems), and varying quantities of template, as described previously. 18 The sequences of the primer pairs for NEK2 amplification were: forward primer, 5 0 -TGCTTCGTGAACTGAAACATCC-3 0 , and reverse primer, 5 0 -CCAGAGTCAACTGAGTCATCACT-3 0 .
Immunoblot analysis
Cells were lysed in lysis buffer (25 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) containing protease inhibitors (aprotinin, leupeptin and PMSF) on ice, and centrifuged at 10,000g at 48C for 30 min. The supernatant was transferred to a new tube, and nuclear extracts isolated as described previously. 19 Total cell lysates (80 lg/lane) or nuclear extracts (20 lg/lane) were fractionated via sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 10% gel. Separated proteins were transferred to a nitrocellulose membrane and visualized using chemiluminescence with an ECL detection kit (Amersham Inc., Piscataway, NJ), as described previously. 20 The intensities of immunoreactive bands were quantified using Image Gauge software (Fuji Film, Tokyo, Japan).
Murine models of tumor progression and drug resistance
For establishment of solid tumors in nude mice (n 5 5/ group), 1 3 10 6 SK-Hep1 or 2 3 10 5 J7 stable cells/100 ll PBS were subcutaneously (s.c.) injected, and tumor volumes measured with calipers once per week after injection. While J7-shNEK tumors were allowed to reach >500 mm 3 in volume, mice were injected intraperitoneally (i.p.) with LipoDox (4 mg/kg body weight) twice per week. Animals were sacrificed at the end of the experiment.
The invasive ability of SK-Hep1-overexpressing NEK2 cells was further determined. To this end, SK-NEK2 or SKNeo control cells (5 3 10 6 ) were injected intravenously into nude mice (n 5 5/group). All animals were sacrificed on Week 7 after tumor inoculation, and livers and lungs removed. Animal experiments were performed in accordance with the United States National Institutes of Health guidelines and the Chang-Gung Institutional Animal Care and Use Committee Guide for Care and Use of Laboratory Animals. Formalin-fixed and paraffin-embedded tissues from lungs of nude mice were examined via immunohistochemistry using a polyclonal antibody against NEK2 (ab115731, Abcam). Positive staining, indicating cancer cells, appeared as a dark brown color showing NEK2 immunoreactivity. All experimental protocol was approved by Chang-Gung Institutional Animal Care and Use Committee (IACUC Approval No. CGU13-016).
Expression plasmid construction and transient transfection
To clone the pcDNA-NEK2 expression vector, fragments of NEK2 cDNA were amplified with the primers 5 0 -CCGGGG TACC ATGCCTTCCCGGGCTGAGGACTAT-3 0 and 5 0 -CCC GCTCGAG CTAGCGCATGCCCAGGATCT-3 0 , based on the published nucleotide sequence (Accession No.: NM002497). The reaction mixture was preheated at 958C for 5 min, followed by 32 cycles at 958C for 1 min, 588C for 1 min, 728C for 1 min 30 sec, and a final step at 728C for 5 min. Amplified full length fragments of NEK2 coding sequence (1338 bp) were digested with KpnI and XhoI, and cloned into the pcDNA3 vector. The cloned sequences were finally confirmed by automated DNA sequencing. Transient transfection in hepatoma cells was performed using the Lipofectamine method. 21 SK-Hep1-overexpressing NEK2 stably transfected clones were established with G418 selection. As a control, SK-Hep1 cells were transfected with the empty vector, yielding a cell line expressing Neo protein (SK-Neo cells).
Knockdown of NEK2 expression with shRNA TRCN0000000950 and TRCN0000000951 clones of short hairpin RNA (shRNA) targeting the NEK2 coding sequence were purchased from the National RNA Interference Core Facility (Institute of Molecular Biology, Academia Sinica, Taiwan). TRCN0000000948 shRNA targets the 3 0 -UTR region of NEK2. These shRNA oligonucleotides were cloned into pLKO.1-Puro vector. The hepatoma cell line, J7, was transduced with lentivirus shRNA, and stably transduced J7-shLuc or J7-shNEK cell lines established. Recombinant lentivirus was produced according to a previously described protocol. 22 Briefly, lentiviral shRNA plasmid was cotransfected into HEK 293T cells along with pCMV R8.91 (packaging plasmid) and pMDG (vesicular stomatitis virus glycoprotein plasmid) via Lipofectamine (31) . Media were changed 24 hr posttransfection, and the supernatant collected 48 hr later. Supernatant fractions were centrifuged (2,000g for 20 min) to remove cellular material and subsequently filtered through a 0.45 lm filter. Supernatant containing recombinant lentiviral particles was either stored at 48C until use or frozen in aliquots at 2808C. J7 cell lines were exposed to recombinant lentivirus overnight and selected using puromycin, starting at 3 days post-transduction.
Soft agar clonogenic and standard apoptosis assays
Cancer cells (10,000/well) were seeded in 12-well plates for layer agar cultures and treated with multiple drugs at different doses for 3 weeks. Cells were resuspended in 0.33% agar in DMEM containing 10% FBS, and the upper layer replaced once a week in complete medium with or without drugs. After 3 weeks, colonies were stained with 0.01% (w/v) crystal violet. Images of all plates were obtained under the microscope (Olympus IX71, Tokyo, Japan), and colony numbers scanned and counted with Image J. Colony size was shown by photos (Scale bar, 400 lm). For the standard apoptosis assay, all procedures followed the standard manufacturer's instructions (Annexin V Apoptosis Detection Kit APC, eBioscience, San Diego, CA). Cells undergoing apoptosis were fixed, early apoptotic stages visualized using fluorochromeconjugated Annexin V, and analyzed using flow cytometry.
Cell proliferation assay
Cells (1 3 10 5 ) were grown on 6-cm dishes. At different time-points, growth rates were assessed with trypan blue exclusion and quantitated using the Countess cell counter (Invitrogen, Carlsbad, CA). Results are presented as fold change relative to control values.
Migration and invasion assays
For migration assays, SK-Hep1 (13 10 5 ) sable transfected cells, J7 (23 10 5 ), and Hep3B (23 10 5 ) stable transduced cells were suspended in 100 ll of serum-free DMEM before being placed in the upper chamber (Costar, St Lowell, Massachusetts); as for the lower chamber, 10% FBS-containing medium was placed as a chemoattractant. For invasion assays, the upper chambers of 24-well transwells (Corning Costar) were coated with diluted Matrigel (100 ll) and incubated at 378C for at least 4-5 hr to allow gelling. Then, hepatoma cells were suspended in 100 ll of serum-free medium before being placed in the upper matrigel-coated chamber and lower well was placed in 10% FBS DMEM. After 24 hr of incubation at 378C, cells on the upper surface of the filter were completely wiped away with a cotton swab, and the lower surface of the filter was stained with crystal violet and counted under a microscope at a magnification of 1003 (Nikon, Tokyo, Japan). For each replicate, the tumor cells in six randomly selected fields were determined, and counted manually with the NIH Image J 3.0 software (National Institutes of Health, Bethesda, Maryland).
Endothelial cell tube formation assay
The day before the tube formation assay, a matrigel matrix was incubated on ice overnight. On the day of the assay, 0.1 ml matrigel matrix was transferred to a 48-well plate.
Plates or slides were incubated at 378C, 5% CO 2 overnight. Human umbilical vein endothelial cells (HUVECs) were trypsinized, and the cells counted and diluted to 3 3 10 4 /100 ll in M-199 medium containing 80 lg conditioned medium from Hep3B, J7 or SK-Hep1 stable cell lines. The mixture was transferred to each well containing the matrigel matrix. Plates were incubated at 378C, 5% CO 2 for 16-20 hr according to the size of the tube.
In vivo matrigel plug angiogenesis assay
Nude mice (7 weeks of age) were administered s.c. injections of 150 ll of Matrigel (Collaborative Biomedical Products, Bedford, MA) at 48C pre-mixed with 150 ll PBS containing 2 3 10 6 J7 or 5 3 10 6 SK-Hep1 stable cells. 23 Following injection (n 5 5/group), the Matrigel rapidly formed a plug. After 7 days, quantitative differences of Matrigel plugs were detected, and images obtained. Hemoglobin was measured using the Drabkin method and Drabkin reagent kit 525 (Sigma-Aldrich, St Louis, MO) for quantitation of blood vessel formation. Concentrations of hemoglobin and relative protein content were calculated from a known amount of hemoglobin.
Immunohistochemical (IHC) staining
IHC was performed on matrigel plug sections and paraffinembedded tissue sections using mouse mAb against CD31 (ab28364, Abcam). The microvessel density (MVD) in tumor tissues or Matrigel plug representing the degree of angiogenesis in vivo was evaluated by staining for CD31, an endothelial cell marker. Any discrete cluster or single cell staining for CD31 was counted as one microvessel. The absolute number of CD31-positive vascular structures was recorded in five randomly selected fields at 2003 magnification for each case using light microscopy. Overall survival of patients as an event was assessed using the log-rank test. Kaplan-Meier survival curves are shown.
The p values <0.05 were considered significant.
Results
NEK2 overexpression is linked to poor survival in liver cancer
Gene expression profiling with DNA microarrays has emerged as a powerful approach to study the cancer transcriptome. Here, we analyzed NEK2 expression from a webbased microarray database and data-mining platform designated ONCOMINE (www.oncomine.org). 24 High levels of NEK2 mRNA were detected in tumor specimens from Roessler and Wurmbach liver datasets, compared with normal tissues (Fig. 1a) . To establish the clinical implication of NEK2 expression in liver cancer, we used Oncomine microarray datasets and associated clinical information on liver cancer. Notably, expression of NEK2 in Roessler dataset was increased in late-stage HCC (TMN stages I vs. III) (Fig. 1b) . NEK2 expression was increased in Wurmbach liver dataset, with stage-dependent upregulation in advanced or very advanced tumors, compared with very early stage. Analysis of NEK2 mRNA in 158 consecutive patients with HCC revealed elevated levels in HCC tissues, compared with non-tumor tissues (Fig. 1c) . Expression of NEK2 was associated with clinicopathological parameters, including pathological stage (I vs. III, p < 0.01), tumor size (5 cm, p < 0.01) and vascular invasion (p < 0.01) (Figs. 1c and 1d, and Table 1 ). To examine NEK2 protein expression in HCC, tissue specimens were subjected to immunoblotting (Fig. 1e) . High NEK2 protein expression was detected (62.8%) in 70 HCC specimens, compared with matched adjacent noncancerous tissues. Moreover, overexpression of NEK2 protein was associated with poor overall survival in patients with HCC (Fig. 1f, p 5 0.028) .
Knockdown of NEK2 expression inhibits hepatoma cell growth, drug resistance, migration and angiogenesis in vitro HCC is characterized by rapid tumor cell growth, early hepatic metastasis, high-grade malignancy and multidrug resistance. The overall 5-year survival rate is only approximately 5%. 25 To examine the functional role of NEK2 in cancer cell survival or migration, two specific shRNAs against the gene were used. Western blots confirmed efficient knockdown of NEK2 in J7 stably transduced cell lines (Fig. 2a) . Depletion of NEK2 effectively reduced J7 cell growth and migration (Figs. 2a and 2b, left panel) . Active migration of tumor cells is a prerequisite for tumor-cell invasion and metastasis. Moreover, metastasis is a complex cell motility progression including invasion. 26 To investigate whether NEK2 involving hepatoma cell invasion, matrigel transwell invasion assays were performed. The invasion ability was also declined in J7-shNEK cells (Fig. 2b, right panel) . To ascertain the effects of NEK2 on cancer cell viability and drug resistance, a clonogenic soft agar assay was performed using J7-shLuc or -shNEK cell lines treated with cisplatin or lipo-doxorubicin (Lipo-Dox). Data from the cell proliferation assay revealed IC 50 values of cisplatin and Lipo-Dox of 11.4 lM and 0.73 lM for J7-shLuc cells, and 4.83 lM and 0.35 lM for J7-shNEK cells, respectively. Drug treatment led to a significant decrease in colony number in shLuc control cells, which was further reduced in shNEK cells. J7 cells with little expression of NEK2 showed a marked decrease in cell viability and colony formation, indicating that knockdown of NEK2 inhibits cancer cell growth (Fig. 2c) . To ascertain whether NEK2 knockdown induces apoptosis, NEK2-silenced J7 cells were cultured for 2 days after drug treatment, and subjected to the standard apoptosis assay. As shown in Supporting Information Figures S1a and S1c, decreased and increased levels of cell viability and apoptosis were observed in NEK2 knockdown cancer cells, respectively, compared with control cells.
Angiogenesis may be a target for combating diseases characterized by either poor vascularization or abnormal vasculature. 27 Clinical data showed an association of high expression of NEK2 with vascular invasion (Table 1) . To clarify whether in vitro angiogenesis is mediated by NEK2, HUVEC proliferation, migration and tube formation assays were determined in J7-shNEK stably transduced cell lines. As shown in Figure   Figure 2d, blockade of NEK2 expression significantly inhibited HUVEC migration and tube formation, but not HUVEC proliferation.
To identify the downstream targets mediated by NEK2, target RNA and protein levels were examined upon knockdown of NEK2. As shown in Supporting Information Figure   Figure 3 . S2a, mRNA levels of several genes, including MMP-2, MMP-9, Snail and Twist, were significantly decreased by NEK2 knockdown (>50%). Gelatin zymography results disclosed that MMP-2 and 29 activities are diminished by NEK2 knockdown (Fig. 2e) . We observed that pAKT, NF-jB and metastasis related proteins including Twist were reduced in J7-shNEK cells (Fig. 2f) .
We further examine the effect of NEK2 knockdown on proliferation, migration and angiogenic response of another hepatoma Hep3B cells (Supporting Information Fig. S3 ). Similarly, NEK2 knockdown in Hep3B cells represses cell growth, migration, invasion, drug resistance and angiogenesis. These results indicate NEK2 may implicate in liver cancer progression.
Increased NEK2 expression induces cell proliferation, migration ability, drug resistance and angiogenesis in hepatoma SK-Hep1 cells
To validate its tumor-promoting role, NEK2 was overexpressed in SK-Hep1 cells via pcDNA-NEK2 vector transfection. Western blots confirmed efficient overexpression of NEK2 in SK-Hep1 stable cell lines (Fig. 3a) . NEK2 overexpression led to significantly enhanced proliferation, compared with empty vector (Neo)-transfected hepatoma cells (Fig. 3a) . Two SK-NEK2 stably transfected cell lines displayed increased migration and invasion, compared with the SK-Neo control cell group (Fig. 3b) . To determine the effects of NEK2 expression on hepatoma cell viability and drug resistance, and clonogenic soft agar assays were performed. SKHep1 cells overexpressing NEK2 showed a significant increase in viability and colony formation, indicating that NEK2 promotes cancer cell survival (Supporting Information Fig. S1b and Fig. 3c) . Furthermore, compared with untreated controls, cancer cells overexpressing NEK2 showed only a slight decrease in capacity to form colonies upon cisplatin or Lipo-Dox treatment at low doses (Fig. 3c) . To confirm whether NEK2-conferred drug resistance is associated with decreased apoptosis, SK-Neo control and SK-NEK2 cell lines were examined after treatment with these drugs for 48 hr. As shown in Supporting Information Figure S1d , overexpression of NEK2 was associated with decreased apoptosis in cells treated with anti-cancer drugs, compared with controls.
In contrast to the angiogenic effect of NEK2 knockdown, overexpression of NEK2 significantly increased HUVEC migration and tube formation (Fig. 3d) . In view of our finding that tube formation is regulated by NEK2 in hepatoma cells, several angiogenesis-related genes were additionally examined (Supporting Information Fig. S4) . Notably, ANGPT1, CCL2, Coagulation Factor III (CF III) and IL-8 genes were upregulated by NEK2.
The downstream targets, including MMP-2, MMP-9, Snail and Twist, were significantly upregulated by NEK2 (>4-fold) (Supporting Information Fig. S2b ). The MMP activities or metastasis related protein levels were decreased by NEK2 knockdown while vice versa it was observed with NEK2 overexpression (Figs. 3e and 3f) .
To further confirm the promoting function of NEK2 in cancer cell survival and migration, rescue experiments were performed. A lentiviral expression system containing shRNA targeting the 3 0 -UTR of NEK2 was used to deplete NEK2 in J7 cells. Western blots confirmed the efficient knockdown of NEK2 (Supporting Information Fig. S5a) . To address the issue of off-target toxicity, J7-shNEK cells were transfected with pcDNA-NEK2 containing only the coding region of NEK2, and drug resistance and migration examined. NEK2 overexpression successfully abrogated inhibition of cell viability after drug treatment, strongly suggesting that cytotoxic effects are induced by specific knockdown of NEK2 (Supporting Information Fig. S5b) . Moreover, Overexpression of NEK2 restored J7-shNEK cell migration to a marked extent (Supporting Information Fig. S5c ).
NEK2 overexpression in hepatoma cells leads to drug resistance via transporter ABCC10
To ascertain the specific gene related to drug resistance was associated with induction of NEK2, qRT-PCR analysis in SK-NEK2 or J7-shNEK cells were performed (Figs. 4a and 4b ). Increased expression of NEK2 led to upregulation of several ABC (ATP-binding cassette) transporter family members, including ABCB1, ABCC4, ABCC10 and ABCG2 (Fig. 4a , p > 0.05). However, ABCC10 expression was significantly decreased in hepatoma J7 NEK2 knockdown cells (Fig. 4b) . We further analyzed the gene expression patterns of the ABC family in a web-based microarray database. High levels of ABCC4, ABCC5 and ABCC10 mRNA were expressed in HCC (Roessler and Wurmbach liver datasets), compared with normal tissues (Fig. 4c) . Expression of the NEK2 gene was positively correlated with that of ABCC10 in two HCC datasets (Fig. 4d) . Consistently, downregulation of NEK2 via shRNA led to decreased ABCC10 expression (Fig. 4b) . Western blot assays showed specific knockdown of ABCC10 in (Fig. 4e) . Knockdown of ABCC10 largely abrogated NEK2-induced drug resistance through suppression of colony formation (Fig. 4f) . These results suggest that ABCC10 mediates resistance to both cisplatin and Lipo-Dox in NEK2-overexpressing hepatoma cells.
SK-NEK2 cells
NEK2 mediates tumor growth, metastasis and angiogenesis in vivo
To validate the role of NEK2 in vivo, hepatoma cells overexpressing NEK2 were subcutaneously injected into nude mice. Subcutaneous xenograft tumors of SK-NEK2 mice displayed increased growth, compared with those injected with SK-Neo control. Tumor weight assessment revealed that relative to the control group, mice with SK-NEK2 contained larger tumors (Fig. 5a and Supporting Information Fig. S6a) . To determine whether the in vitro results on migration and invasion are applicable in vivo, nude mice were injected with SK-NEK2 or Neo control cells. The metastatic index was approximately 2.8 times higher in SK-NEK2 mice than those injected with Neo-control cells (Fig. 5b and Supporting Information Fig. S6b ). The tumor size relative to the average tumor area (per cm 2 lung section in the SK-NEK2/Neo-control mice) was about five times larger in SK-NEK2 than SKNeo mice. We additionally tested the effects of knockdown of NEK2 on liver cancer cell growth in vivo. Compared with hepatoma J7-shLuc knockdown control, subcutaneous xenograft tumors of J7-shNEK displayed reduced growth. As shown in Figure 5c , on Day 23, tumors of J7-shLuc showed rapid growth while knockdown of NEK2 resulted in marked inhibition of tumor growth and decrease in tumor volume (Fig. 5d) . On Day 20 after engraftment of tumors, we examined whether downregulation of NEK2 expression increases drug sensitivity to Lipo-Dox in NEK2-depleted J7 stable cell lines. Lipo-Dox was administered via intraperitoneal injection at the time J7-shLuc tumors reached a large volume (>600 mm 3 ). Our data showed that knockdown of NEK2 inhibits tumor growth and Lipo-Dox further suppresses growth specifically in tumors with downregulated NEK2.
Active angiogenesis is one of the key factors underlying rapid recurrence and poor survival of HCC. 17 To elucidate whether NEK2 mediates angiogenesis in vivo, hepatoma cells with overexpression or depletion of NEK2 were subcutaneously injected into nude mice. The matrigel plug assay was used to confirm angiogenesis in vivo, and the microvessel density of CD31-stained sections of xenografts or relative hemoglobin analyzed (Fig. 5e) . SK-NEK2-derived tumors displayed a significant increase in blood vessels, compared with those of the control group (Fig. 5f ). To confirm the above findings, knockdown of NEK2 in hepatoma J7 cells was verified via matrigel plug assay. J7-shNEK derived tumors displayed decreased angiogenesis, compared with those derived from J7-shLuc control (Supporting Information Figs. S6c and S6d). The collective findings indicate that NEK2 induces tumor growth, metastasis and angiogenesis in vivo.
Overexpression of NEK2 activates pAKT/NF-jB signaling to increase hepatoma cell growth, migration and angiogenesis
Our experiments clearly demonstrate that NEK2 mediates proliferation, migration and angiogenesis. Moreover, cytosolic pAKT activation and nuclear accumulation of NF-jB were increased in NEK2 overexpression cells (Fig. 6a) . The specific PI3K, NF-jB and AKT inhibitors suppressed activation of cell growth in SK-NEK2 cells ( Fig. 6b and Supporting Information Fig. S7a ). Activation of PI3K/AKT signaling has been shown to induce cancer cell survival and drug resistance. 28 Our results
further demonstrated a functional role of NEK2-mediated PI3K/AKT and NF-jB signaling in hepatoma cancer cell growth ( Fig. 6b and Supporting Information Fig. S7a) . The downstream targets, including MMP-2, MMP-9, IL-8 and Twist, were significantly upregulated by NEK2 (Supporting Information Figs. S2 and S4). Our results imply that NEK2 may lead to several downstream genes activation via pAKT and NF-jB signaling. Twist is a downstream target of NF-jB and its involvement can block apoptosis induced by chemotherapeutic agents. 29 Moreover, Twist activation is highly association with Akt pathway. 30 Our results also showed that knockdown of Twist markedly abrogated NEK2-induced drug resistance by colony formation assays (Supporting Information Fig. S8 ).
To clarify the signaling pathway involving migration, SK-NEK2 cells were treated with these inhibitors. As shown in Figure 6c , treatment with PI3K, NF-jB and AKT inhibitors led to significantly disrupted NEK2-mediated migration. To elucidate whether NEK2 enhances migration ability via activation of downstream target MMP proteins, NF-jB expression was eliminated in SK-NEK2 and control cells (Fig. 6d) . Similar to the effects of NF-jB inhibition, knockdown of NFjB in SK-Hep1 cells overexpressing NEK2 abrogated NEK2-induced migration (Fig. 6d) . Notably, MMP-2 and 29 levels were suppressed upon suppression of NF-jB (p50) in SK- NEK2 cells. NEK2-induced migration was completely eradicated upon knockdown of NF-jB, and partially eradicated upon knockdown of MMP2 (Fig. 6d) .
To confirm whether NEK2 mediated NF-jB signaling in angiogenesis, several inhibitors were used to examine the signaling involvement. In vitro angiogenesis assays revealed that NEK2 contributes to angiogenesis via PI3K/AKT and NF-jB signaling ( Fig. 6e ; Supporting Information Figs. S7b and S7c). Additionally, our results showed that IL-8 levels were induced by NEK2 overexpression (Supporting Information  Fig. S4 ). Previous study reported that IL-8 induced by NF-jB may lead to the pathogenesis of angiogenesis. 31 To further Figure 6 .
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validate the involvement of NF-jB signaling, NF-jB (p50) or IL-8 shRNA knockdown approach was employed. These results displayed that NEK2 mediates in vitro angiogenesis via NF-jB signaling and IL-8 induction (Fig. 6f) .
Based on these findings, we propose that NEK2 mediates hepatoma cell responses, including growth, migration and angiogenesis, via PI3K/AKT and NF-jB signaling pathways.
Discussion
Liver cancer is the leading cause of cancer-related mortality. Survival tends to be poor, most likely because of the high frequency of tumor recurrence and metastasis after treatment. 25 Active angiogenesis and metastasis underlie the rapid recurrence and poor survival of HCC. 17 Hence, identification of suitable, novel therapeutic targets is essential for developing effective strategies to improve the prognosis of HCC. The specific role of NEK2 in liver cancer progression is largely unknown at present. In this study, we demonstrated that overexpression of NEK2 is associated with cell proliferation, drug resistance, metastasis and angiogenesis in HCC. NEK2 expression levels in a large set of tumors and non-tumor controls were analyzed using the Oncomine dataset. High levels of NEK2 were associated with tumor volume, vascular invasion and pathological stage in HCC. Moreover, overexpression of NEK2 protein in HCC was associated with poor survival outcome. Recent study suggests that NEK2 could be a promising biomarker for HCC recurrence. 32 High NEK2 expression was positively correlated with hepatic venous invasion, des-gammacarboxy prothrombin, and a-fetoprotein. Consistent with our observation, NEK2 overexpression leads to hepatoma metastasis and angiogenesis. Furthermore, our results demonstrated that NEK2 overexpression was correlated with tumor size. However, the statistically differences of clinicopathological factors involving NEK2 overexpression in HCC may be due to different study population. Our findings collectively support an oncogenic role of the NEK2 gene in liver cancer. Moreover, PI3K/AKT-NFjB signaling appears to be involved in NEK2-induced liver cancer cell drug resistance, migration and angiogenesis. Previous reports have shown that NEK2 binds and phosphorylates PP1 in myeloma cells, leading to upregulation of phosphorylated AKT at Ser-473. 10 A recent study reported that downregulation of NEK2 inhibits activation of the MAPK pathway. 11 In our experiments, overexpression of NEK2 protein in hepatoma cells not only enhanced cell survival and drug resistance, but also promoted metastasis and angiogenesis via the PI3K/AKT-NFjB signaling pathway. ABC transporter family members, ABCB1, ABCC1 and ABCG2, play a crucial role in the development of multi-drug resistance. 33 Our results suggest that NEK2 induces the expression of several ABC transporters, including ABCC10. Conversely, knockdown of ABCC10 abrogates NEK2-mediated drug resistance of hepatoma cells. Survival signals from downstream targets of AKT and subsequent NF-jB activation mediate transcriptional regulation of the BCL-2 gene. 34 In this study, we clearly showed that NEK2 induces several prosurvival genes expression. The PI3K, NF-jB and AKT inhibitors suppressed NEK2-induced colony formation, strongly suggesting that NEK2 promotes cell proliferation through activation of PI3K-AKT and NF-jB signaling. Collectively, our in vitro data indicate that the pAKT and NF-jB signaling pathways are involved in NEK2-induced liver cancer drug resistance. Recently, Lin et al. reported that NKE2 expression contributed the cancer stem cell-like properties in HCC, including the self-renewal and chemotherapeutic resistance properties. 35 Consistent to our results, NEK2 knockdown was more sensitive to cisplatin in hepatoma J7 or Hep3B cells. Our data as well displayed that NEK2 overexpression leads to ABCG2 expression. However, ABCG2 levels were slightly reduced while NEK2 was knocked down in hepatoma J7 cells. This may be resulted in the context of different hepatoma cells. They also demonstrated the significant role of NEK2 in maintaining self-renewal property via Wnt/b-catenin signaling. Similarly, our data showed that NEK2 mediates the expression of b-catenin. Additionally, NEK2 leads to drug resistance via increased levels of ABCC10 and Twist. Recent report showed that the expression of ABC transporters was dispensable for the chemoresistance mediated by Twist1 and Snail. 36 Twist may play a role in the generation of hepatocellular cancer stem cell phenotype through upregulation CD133 and CD44. 37 These results suggested that NEK2 mediates drug resistance via regulation of downstream targets expression. Overexpression of NEK2 consistently enhanced tumor growth in vivo. Moreover, knockdown of NEK2 repressed liver cancer cell growth and Lipo-Dox resistance in vivo. These results support targeting of the NEK2 gene as a potential strategy to eradicate drug-resistant cells.
NF-jB activation in liver cells has a dramatic effect on the development of HCC, constituting one of the major causes of cancer-related death. 38 HCC is highly resistant to currently available chemotherapeutic agents, with no effective treatment options and poor prognosis. MMPs are significantly involved in cancer invasion and metastasis via degradation of basement membrane. 39 MMP-2 overexpression is reported in various human cancers, including HCC.
40 S100A4 has been shown to contribute to HCC metastasis via activation of NFjB-dependent MMP-9 expression. 41 Our results showed that MMP-2 and 29, and not S100A4, induced by NEK2 mediates hepatoma cell migration, dependent on NF-jB activation. Previous studies additionally suggest that IL-8 induced by hypoxia and mediated by NF-jB contributes to the pathogenesis of intraocular neovascularization. 31 IL-8 overexpression of HCC may dictate the development of the inflammatory micro-environment. 42 Similarly, our in vitro data indicate that overexpression of NEK2 and NF-jB activation promotes angiogenesis via IL-8 expression. Moreover, Twist is also a target of NF-jB and its dispensable involvement in proliferation, drug resistance, angiogenesis and HCC metastasis. 30 In conclusion, NEK2 is capable of inducing tumor drug resistance, metastasis, and angiogenesis via downstream genes activation including ABCC10, Twist, MMP2, MMP9 and IL-8. As a potentially significant carcinogenic factor, NEK2 may present a promising therapeutic target in tumorigenesis, progression and prognosis of primary liver cancer and facilitate the development of alternative strategies for clinical drug research.
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